In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Equillium (EQ), with a price target of $12.00. The company’s shares closed last Friday at $6.13, close to its 52-week low of $2.53.
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 12.8% and a 51.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Protalix Biotherapeutics, EyePoint Pharmaceuticals, and Bausch Health Companies.
Currently, the analyst consensus on Equillium is a Strong Buy with an average price target of $13.60, implying a 107.6% upside from current levels. In a report issued on June 8, JonesTrading also maintained a Buy rating on the stock with a $14.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.05 and a one-year low of $2.53. Currently, Equillium has an average volume of 166K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline include EQ001, is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.
